🔗 Share this article The Global Health Body Sounds Alert Over Severe Shortage of Obesity Jabs Fewer than a tenth of individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it issues its first advice on the medications. Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments. Per forecasts, over two billion could be obese by 2030 unless action is taken. "Our new guidance affirms that obesity is a long-term condition that can be addressed with holistic and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are major hurdles to widespread access to the treatments that can aid individuals in losing substantial body mass, explains the body. Weight-Loss Drug Scarcity Even in the present most favorable scenario, the production of such drugs might only reach around 100 million people – under 10% of those who need them, according to the health organization. The advice calls on nations and manufacturers to expand access, through strategies such as licensing agreements. The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026. The Way Obesity Drugs Work GLP-1 drugs imitate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals reduce food intake. People typically see weight reduction in the initial weeks of beginning the once-weekly jabs. Evidence points to people may regain a significant portion after a year of stopping the treatment, as their typical appetite return. To be overweight or obese increases your likelihood for experiencing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers. Obesity concerns people in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.
Fewer than a tenth of individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it issues its first advice on the medications. Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments. Per forecasts, over two billion could be obese by 2030 unless action is taken. "Our new guidance affirms that obesity is a long-term condition that can be addressed with holistic and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are major hurdles to widespread access to the treatments that can aid individuals in losing substantial body mass, explains the body. Weight-Loss Drug Scarcity Even in the present most favorable scenario, the production of such drugs might only reach around 100 million people – under 10% of those who need them, according to the health organization. The advice calls on nations and manufacturers to expand access, through strategies such as licensing agreements. The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026. The Way Obesity Drugs Work GLP-1 drugs imitate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals reduce food intake. People typically see weight reduction in the initial weeks of beginning the once-weekly jabs. Evidence points to people may regain a significant portion after a year of stopping the treatment, as their typical appetite return. To be overweight or obese increases your likelihood for experiencing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers. Obesity concerns people in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.